Table 3.
Changes in UACR, eGFR, and baPWV During the Treatment Period (Intention‐to‐Treat Populations)
| Change | ALI/AML Group (n=45) | h‐dAML Group (n=51) | P Value |
|---|---|---|---|
| UACR, mg/g cr | |||
| Baseline | 26.3 (18.6–37.2) | 21.4 (15.4–29.8) | .39 |
| End of study | 22.4 (16.3–30.7) | 27.4 (19.1–39.2) | .40 |
| Change after 16 weeks, % | −15.0 (−33.3 to 8.4) | 27.9 (−0.4 to 64.1) | .02 |
| eGFR, mL/min/1.73 m2 | |||
| Baseline | 70.4±19.2 | 71.0±17.2 | .86 |
| End of study | 67.8±18.4 | 69.3±18.0 | .64 |
| Change after 16 weeks | −2.5±7.2a | −1.7±6.3 | .54 |
| baPWV, cm/s | |||
| Baseline | 1894.5±327.8 | 2016.2±360.9 | .10 |
| End of study | 1837.7±326.6 | 1927.1±318.3 | .20 |
| Change after 16 weeks | −56.8±204.7 | −89.1±239.6a | .50 |
Abbreviations: eGFR, estimated glomerular filtration rate; UACR, urine albumin to creatinine ratio. Data are expressed as mean±standard deviation or geometric mean (95% confidence interval). Laboratory data were evaluated in 45 patients in the aliskiren/amlodipine (ALI/AML) group and in 51 patients in the high‐dose amlodipine (h‐dAML) group. Brachial‐ankle pulse wave velocity (baPWV) was evaluated in 41 patients in the ALI/AML group and in 48 patients in the h‐dAML group. a P<.05 vs baseline by paired t test.